Exploring the therapeutic potential of precision T-Cell Receptors (TCRs) in targeting KRAS G12D cancer through <i>in vitro</i> development.

导出 OA

翻译打印收藏纠错

第一作者： Weitao,Zheng

第一单位： Sino-German Biomedical Center, National "111" Center for Cellular Regulation and Molecular Pharmaceutics, Cooperative Innovation Center of Industrial Fermentation (Ministry of Education of China & Hubei Province), Hubei University of Technology, Wuhan, 430068, China.

作者： Weitao,Zheng ^[1] ; Dong,Jiang ^[2] ; Songen,Chen ^[1] ; Meiling,Wu ^[1] ; Baoqi,Yan ^[2] ; Jiahui,Zhai ^[2] ; Yunqiang,Shi ^[2] ; Bin,Xie ^[1] ; Xingwang,Xie ^[2] ; Kanghong,Hu ^[1] ; Wenxue,Ma ^[3]

作者单位： Sino-German Biomedical Center, National "111" Center for Cellular Regulation and Molecular Pharmaceutics, Cooperative Innovation Center of Industrial Fermentation (Ministry of Education of China & Hubei Province), Hubei University of Technology, Wuhan, 430068, China. ^[1] Center of Research & Development, Beijing CorreGene Biotechnology Co., Ltd., Beijing, 102206, China. ^[2] Department of Medicine, Sanford Stem Cell Institute and Moores Cancer Center, University of California San Diego, La Jolla, CA 92093, USA. ^[3]

关键词 Alloreactivity G12D Kirsten rat sarcoma virus (KRAS)T cell receptor (TCR)TCR therapy Tumor-infiltrating lymphocytes (TILs)